12月26日，以"新开局、新动能、新征程"为主题的"启航·2025金融峰会"在北京圆满举办，大会由金融界主办，汇聚监管部门、行业协会、金融机构、上市 公司、媒体等数百位相关领导和重磅嘉宾。会上，第十四届金融界"金智奖"年度评选结果重磅揭晓，巨子生物荣获"杰出成长性企业"。 "金智奖"旨在树立高质量发展标杆，引导上市公司聚焦主业、持续创新、践行社会责任，推动资本向优质企业集聚。本届评选中，金融界上市公司研究院紧 密契合"十五五"规划建议中"提升上市公司质量"的要求，将高质量发展内核分解为社会责任、实业贡献、投资回报、成长前景、创新效率、杰出品牌六大维 度，以企业财务数据和公开信息为基础建立量化分析模型，最终覆盖A股、港股及中概股超8000家企业，评选出近200家获奖企业。 "杰出成长性企业"奖项的核心标准在于综合考察企业的持续增长潜力与高质量发展能力，重点考量企业在主业深耕、创新驱动、市场拓展、运营效率等关键 维度的综合表现。该奖项的设立，旨在挖掘具备长期发展韧性的优质企业，引导企业坚守创新初心、夯实成长根基，为实体经济高质量发展注入新活力，是 反映行业成长趋势、彰显企业发展潜力的重要标杆。 作为专业皮肤护理领 ...

转自：新华财经 而随着2026跨年元旦等节日来临，京东时尚秒送也推出美妆护肤礼盒、运动鞋服、内衣礼盒等热门节日 大牌爆款限时低至5折等超值优惠福利，为更多消费者即时带来贴心的节日礼赠心意。 京东时尚秒送的快速发展，不仅持续丰富了即时零售市场生态，更助力合作品牌高效拓展线上增量市 场、提升运营效率。未来，京东时尚秒送将继续携手更多合作伙伴，不断拓展服务与履约能力，聚焦应 急、换季、礼赠等消费者痛点场景，保障商品品质和送达时效，让"随时随地、即想即得"的时尚消费体 验成为常态。 编辑：王菁 截至2025年底，京东时尚秒送累计入驻商家超千家，包括滔搏、安踏、李宁、鸿星尔克、波司登、特步 等国内零售巨头、服饰运动大牌；营业门店数量同比增长超150%，覆盖了包括服装、鞋靴、内衣、美 妆、运动户外等多个核心品类，持续为消费者提供更丰富、更便捷的即时时尚消费体验。 2025年，品牌商家也通过京东时尚秒送实现了销售新增量。年初至今，耐克、阿迪达斯、骆驼、安踏等 运动户外品牌成交额同比增长均超2倍，内衣品牌松山棉店成交额同比增长5倍；随着冬季保暖需求增 加，自11月波司登入驻京东秒送以来，其销售也呈现高增长态势。 除此以外，京 ...

截至2025年底，京东时尚秒送累计入驻商家超千家，包括滔搏、安踏、李宁、鸿星尔克、波司登、特步等国内零售巨头、 服饰运动大牌；营业门店数量同比增长超150%，覆盖了包括服装、鞋靴、内衣、美妆、运动户外等多个核心品类，持续为 消费者提供更丰富、更便捷的即时时尚消费体验。 在数字经济与消费转型的双重驱动下，即时零售正用"分钟级履约"重新定义商业效率的天花板。根据商务部研究院发布的 《即时零售行业发展报告（2025）》，2026年我国即时零售规模将突破1万亿元，预计到2030年，将达到2万亿元。构建良 好生态，推动高质量发展将是即时零售行业的重要议题。京东时尚秒送在2025年全面加速服饰、运动、美妆等核心品类供 给布局，迎来爆发式增长，已成为品牌布局即时零售、消费者获取潮流商品的重要方式。 2025年，品牌商家也通过京东时尚秒送实现了销售新增量。年初至今，耐克、阿迪达斯、骆驼、安踏等运动户外品牌成交 额同比增长均超2倍，内衣品牌松山棉店成交额同比增长5倍；随着冬季保暖需求增加，自11月波司登入驻京东秒送以来， 其销售也呈现高增长态势。 除此以外，京东时尚秒送在重要节日期间增长也尤为显著。近年来，受送礼观念日常化、礼 ...

Investment Rating - The report maintains a "Buy" rating for the company [2][16]. Core Insights - The approval of the first recombinant type I natural sequence collagen facial injection product in China marks a significant milestone for the company, enhancing its competitive position in the medical aesthetics market [7]. - The new product is expected to drive revenue growth and reshape the competitive landscape in the collagen product category, showcasing the company's technological and industrial capabilities [7]. - The company has demonstrated strong revenue growth across its product lines, with notable performance from its flagship products and new launches [7]. Financial Data and Profit Forecast - Projected revenue growth from 2023 to 2027 shows a significant increase, with revenues expected to rise from 3,524 million RMB in 2023 to 10,691 million RMB in 2027, reflecting a compound annual growth rate (CAGR) of approximately 49% [6][8]. - The net profit attributable to the parent company is forecasted to grow from 1,452 million RMB in 2023 to 3,726 million RMB in 2027, with a CAGR of around 23% [6][8]. - The company's gross margin is expected to remain stable, averaging around 82% over the forecast period [6]. Product Performance and Market Position - The flagship product, "可复美," generated revenue of 25.4 billion RMB in the first half of 2025, representing a year-on-year growth of 22.7% [7]. - The company has successfully launched new products that have gained market recognition, contributing to overall revenue growth [7]. - Direct sales channels have shown strong growth, with direct sales revenue reaching 23.3 billion RMB in the first half of 2025, up 26.5% year-on-year [7].

Core Insights - The medical beauty industry is witnessing a competitive showdown between two leading companies, Juzhi Biotechnology and Huaxi Biotechnology, with contrasting financial performances in the first half of 2025 [1][8][14] - Juzhi Biotechnology reported a revenue of 3.113 billion RMB and a net profit of 1.182 billion RMB, achieving a net profit margin of 38%, while Huaxi Biotechnology experienced a 19.57% decline in revenue to 2.261 billion RMB and a 35.38% drop in net profit to 221 million RMB, marking its worst performance in seven years [1][8] Juzhi Biotechnology: Growth Drivers and Potential Concerns - Juzhi's growth is attributed to the synergy of products, channels, and brand, with professional skin care products accounting for 99.7% of total revenue [3][4] - The revenue from functional skin care products reached 2.410 billion RMB, a 24.2% increase year-on-year, primarily driven by the sales of key products [3][4] - Despite strong revenue growth, the company faces challenges such as a slight decrease in gross margin to 81.7% and increased sales and administrative expenses, leading to a rise in overall expense ratio to 38.8% [3][4][5] - The company heavily relies on its two main brands, Kefu Mei and Keli Jin, which together contribute 97.8% of revenue, raising concerns about its growth potential and risk exposure [5][6] Huaxi Biotechnology: Struggles and Strategic Reforms - Huaxi's performance has been under pressure, with a significant decline in its functional skin care segment, which accounts for over 40% of its business, down 34% [8][9] - The company has implemented drastic cost-cutting measures, reducing sales expenses by 39.86% in the second quarter, and has shifted its focus from scale to efficiency in brand promotion [9][10] - Huaxi has also streamlined its R&D efforts by eliminating 88 non-technical brand incubation projects and reallocating resources towards high-barrier products and medical terminal businesses [10][11] - Despite these reforms, Huaxi faces ongoing challenges, including a shrinking traditional hyaluronic acid market and the need for new high-end products to achieve significant sales [11][12] Industry Dynamics and Future Outlook - The competition between Juzhi and Huaxi reflects a broader shift in the medical beauty industry from marketing-driven growth to a focus on technological advancements and product innovation [14][15] - As regulatory scrutiny increases and consumer demand for genuine technological efficacy rises, both companies must adapt their strategies to maintain competitive advantages [14][15] - The outcome of this rivalry will serve as a critical case study for the industry, highlighting the importance of balancing marketing with substantial R&D investments to ensure long-term sustainability [15]

Core Viewpoint - The company reported strong revenue and profit growth in the first half of 2025, driven by the performance of its brands and online sales channels [1][4]. Financial Performance - In 1H2025, the company achieved revenue of 3.11 billion yuan, a year-on-year increase of 22.5% [1] - The net profit attributable to shareholders was 1.18 billion yuan, up 20.2% year-on-year [1] - Adjusted net profit reached 1.21 billion yuan, reflecting a 17.4% increase compared to the previous year [1] Product Performance - The company's professional skincare products generated revenue of 3.10 billion yuan, with a growth rate of 22.5% [1] - Efficacy skincare products accounted for 2.41 billion yuan in revenue, growing by 24.2% and representing 77.4% of total revenue [1] - The medical dressings segment generated 690 million yuan, with a year-on-year growth of 17.1% [1] - The company's brands, 可复美 and 可丽金, reported revenues of 2.54 billion yuan and 500 million yuan, respectively, with growth rates of 22.7% and 26.9% [1][2] Sales Channels - Direct-to-consumer (DTC) online sales reached 1.82 billion yuan, up 13.3% year-on-year [2] - E-commerce platform sales surged to 390 million yuan, a significant increase of 133.6% [2] - Offline direct sales grew to 120 million yuan, reflecting a 74.3% increase [2] - The company has expanded its offline presence with 24 brand stores across various cities by the end of 1H2025 [3] Market Expansion - 可复美 has entered the Southeast Asian market by partnering with Watsons in Malaysia [3] - The company continues to enhance its online multi-platform strategy and refine operations, benefiting from the rapid expansion of beauty categories on platforms like JD.com [3] Profitability and Cost Management - The company's gross margin slightly decreased by 0.7 percentage points to 81.7%, attributed to changes in product mix and a decline in the proportion of high-margin medical dressing revenue [3] - Sales, management, and R&D expense ratios were 34.0%, 2.7%, and 1.3%, respectively, with a decrease in sales expense ratio due to a higher proportion of low-cost channels [3] Future Outlook - The company anticipates accelerated growth in the second half of the year, driven by increased brand marketing efforts and the potential approval of new medical aesthetic products [4] - The adjusted net profit forecasts for 2025-2027 are 2.59 billion, 3.45 billion, and 4.48 billion yuan, respectively [4]

Core Viewpoint - The company is experiencing steady growth in revenue and net profit, with a focus on cost control and the performance of key products and new launches [1][2]. Group 1: Financial Performance - In H1 2025, the company reported revenue of 31.13 billion RMB, a year-on-year increase of 22.5%, and a net profit attributable to shareholders of 11.82 billion RMB, up 20.2% [1]. - The adjusted net profit for H1 2025 was 12.05 billion RMB, reflecting a 17.4% year-on-year growth [1]. - The gross margin for H1 2025 was 81.7%, a decrease of 0.7 percentage points year-on-year, primarily due to changes in product mix and an increase in the proportion of skincare products [1]. Group 2: Cost Management - The company has effectively controlled expenses, with sales expense ratio, management expense ratio, and R&D expense ratio at 34%, 2.7%, and 1.3% respectively, showing a decrease of 1.1, an increase of 0.1, and a decrease of 0.6 percentage points year-on-year [1]. - The net profit margin for H1 2025 was 38%, down 0.6 percentage points year-on-year, but the gross sales difference improved year-on-year [1]. Group 3: Product Development and Market Performance - The company launched the upgraded Collagen Stick 2.0 under its main brand, which focuses on basal membrane barrier repair and achieved top sales during the 618 shopping festival [3]. - The company is focusing on new product launches, including the Rejuvenation Series and the Star Cream, which continue to perform well in the market [3]. - The DTC online direct sales channel and e-commerce platform sales saw significant growth, with revenue of 18.16 billion RMB and 3.91 billion RMB respectively, reflecting year-on-year increases of 13% and 134% [2].

Investment Rating - The report maintains a "Buy" rating for the company [4][7] Core Insights - The company achieved a revenue of 3.113 billion yuan in H1 2025, representing a year-on-year growth of 22.5%, and a net profit attributable to the parent company of 1.182 billion yuan, up 20.2% year-on-year [1] - The gross margin for H1 2025 was 81.68%, a slight decrease of 0.72 percentage points year-on-year, while the net margin was 37.99%, down 0.61 percentage points year-on-year [1] - The sales expense ratio improved by 1 percentage point year-on-year to 34.01%, while the management expense ratio increased by 0.07 percentage points to 2.65% [1] Revenue and Profit Growth - The company's brand "可复美" generated revenue of 2.54 billion yuan in H1 2025, with a year-on-year increase of 22.7% [2] - The "可丽金" brand achieved revenue of 500 million yuan, reflecting a growth of 26.9% year-on-year [2] Channel Performance - Direct sales channels contributed 2.325 billion yuan in revenue, accounting for 74.7% of total revenue, with DTC channels generating 1.816 billion yuan [3] - The company has expanded its offline presence, covering approximately 1,700 public hospitals and 3,000 private hospitals and clinics, along with over 130,000 pharmacy stores [3] Financial Forecast - The company is projected to achieve net profits of 2.505 billion yuan, 3.102 billion yuan, and 3.732 billion yuan for the years 2025, 2026, and 2027, respectively, with corresponding P/E ratios of 21, 17, and 14 [4][6]

Group 1 - The core viewpoint of the articles highlights the robust performance growth of the companies, with 巨子生物 achieving a revenue of RMB 3.11 billion, a year-on-year increase of 22.5%, and a net profit of RMB 1.18 billion, up 20.6% [1] - The revenue growth for 巨子生物 is attributed to deepening online and offline channels, enhancing operational capabilities, consolidating star products, upgrading core products, and strengthening brand marketing [1] - 可丽金 reported a sales revenue of RMB 502.7 million, a 26.9% increase compared to the same period in 2024, accounting for 16.1% of total revenue, driven by online channel expansion and successful upgrades of star products [2] Group 2 - 巨子生物 invested RMB 41 million in R&D, representing 1.3% of its revenue, with over 140 projects under research and 186 patents authorized or applied for [1] - 可丽金's products are available in approximately 1,700 public hospitals, 3,000 private hospitals and clinics, over 130,000 chain pharmacies, and around 6,000 CS/KA stores, utilizing various online platforms for sales and promotion [2] - Looking ahead to the second half of 2025, 可丽金 plans to strengthen its technological research and brand communication, ensuring sustainable and high-quality operational capabilities [2]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights the rapid development of the "New Oxygen Youth Clinic" and the significant changes in the shareholding structure of "Beautiful Garden" following the exit of major shareholder CPE [5][24] - The report emphasizes the importance of emotional consumption themes and recommends high-quality companies in high-growth sectors [8][29] Summary by Sections Retail Market Overview - The retail industry index closed at 2152.72 points, down 0.16%, underperforming the Shanghai Composite Index which rose by 1.40% [7][14] - The retail sector has seen a decline of 3.85% year-to-date [14][17] Industry Dynamics - CPE plans to sell approximately 51.33 million shares (about 21.77%) of "Beautiful Garden," leading to a significant change in the company's shareholding structure [5][24] - "New Oxygen" has transformed from an online platform to a chain of clinics, with a 551% year-on-year increase in revenue for its chain business in Q1 2025 [5][27] Investment Recommendations - Investment Theme 1: Focus on differentiated product capabilities and consumer insights in the gold and jewelry sector, recommending companies like "Old Shop Gold," "Chao Hong Ji," and "Zhou Dafu" [8][29] - Investment Theme 2: Emphasize retail companies that actively adapt to trends, recommending "Yonghui Supermarket" and "Aiying Room" [8][29] - Investment Theme 3: Highlight domestic beauty brands with strong differentiation, recommending "Mao Ge Ping," "Po Lai Ya," and "Shang Mei" [8][30] - Investment Theme 4: Focus on differentiated medical beauty product manufacturers, recommending "Ai Mei Ke" and "Ke Di-B" [8][30] Company-Specific Insights - "Zhou Dafu" reported a revenue of 896.56 million HKD for FY2025, down 17.5%, with a focus on improving product structure and store quality [36][37] - "Old Shop Gold" achieved a revenue of 8.506 billion CNY for FY2024, up 167.5%, with a strong brand expansion strategy [31][32] - "Chao Hong Ji" reported a revenue of 2.252 billion CNY in Q1 2025, up 25.4%, driven by differentiated product offerings [39][40] - "Zhou Da Sheng" faced revenue pressure with a 47.3% decline in Q1 2025, but future growth potential is anticipated through brand optimization [42]